Formulary Watch |

All News - Page 17

Lilly’s Weight Loss Drug Approved by the FDA
Lilly’s Weight Loss Drug Approved by the FDA
Lilly’s Weight Loss Drug Approved by the FDA
November 8, 2023
Tirzepatide, with the brand name Zepbound, is expected to be available by the end of the year in six doses at a list price of $1,059.87, which is about 20% lower than semaglutide.
Postpartum Depression Therapy to Launch with $15,900 Price
Postpartum Depression Therapy to Launch with $15,900 Price
Postpartum Depression Therapy to Launch with $15,900 Price
November 8, 2023
Zurzuvae, the first oral therapy for postpartum depression, will launch in December.
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
How Magellan’s Behavior Health Program Saved up to $4,300 PMPY
November 7, 2023
Using an AI platform, Magellan Health was able to better support providers in prescribing behavioral health medications and addressing medication problems, which reduced pharmacy costs and increased adherence.
Optum Rx Announces Formulary Exclusions for 2024
Optum Rx Announces Formulary Exclusions for 2024
Optum Rx Announces Formulary Exclusions for 2024
November 6, 2023
First in class, biosimilars, oncology drugs and even some generics have been added to Optum Rx’s list of exclusions for 2024.
ICER: Greater Transparency of Coverage Policies Needed
ICER: Greater Transparency of Coverage Policies Needed
ICER: Greater Transparency of Coverage Policies Needed
November 3, 2023
The Institute for Clinical and Economic Review’s fair access report found that for the drugs assessed, formularies provided fair access, but it was difficult to determine how well that translates into real-world access and affordability for patients.
Payer Coverage of Biosimilars Varies by Preference
Payer Coverage of Biosimilars Varies by Preference
Payer Coverage of Biosimilars Varies by Preference
October 31, 2023
A poster from AMCP Nexus quantified tends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still varies.
CarePartners Adds Yuflyma to its Cost Savings Program
CarePartners Adds Yuflyma to its Cost Savings Program
CarePartners Adds Yuflyma to its Cost Savings Program
October 30, 2023
The Humira biosimilar Yuflyma will be available through CarePartners specialty pharmacy business, which has 10 million plan members.
J&J Warns of Risk of Respiratory Depression with Spravato
J&J Warns of Risk of Respiratory Depression with Spravato
J&J Warns of Risk of Respiratory Depression with Spravato
October 27, 2023
Based on reports from post-marketing experience, Spravato’s warnings and precautions section now includes the risk of respiratory depression.
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
October 27, 2023
The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
Subcutaneous Leqembi Clears More Amyloid than IV Formulation
October 26, 2023
In new data, 60% of the patients with early stage Alzheimer’s disease and who have low levels of the protein tau achieved cognitive improvement when treated with Leqembi.
FDA Approves First Subcutaneous Infliximab for IBD
FDA Approves First Subcutaneous Infliximab for IBD
FDA Approves First Subcutaneous Infliximab for IBD
October 23, 2023
Zymfentra is a subcutaneous version of infliximab.
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
October 20, 2023
Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
October 19, 2023
The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.
Questions Remain about Nonprescription Opill
Questions Remain about Nonprescription Opill
Questions Remain about Nonprescription Opill
October 16, 2023
Whether Opill (norgestrel) truly broadens access to daily contraception will depend on Medicaid coverage, requirements under the ACA and pharmacist prescribing.
© 2025 MJH Life Sciences

All rights reserved.